Unione Europea - ceco - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

n.v. organon, oss array - 16348 etorikoxib - potahovaná tableta - 30mg - etorikoxib

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

n.v. organon, oss array - 16348 etorikoxib - potahovaná tableta - 60mg - etorikoxib

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

n.v. organon, oss array - 16348 etorikoxib - potahovaná tableta - 90mg - etorikoxib

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 16461 natrium-mykofenolÁt - enterosolventní tableta - 180mg - kyselina mykofenolovÁ

Unione Europea - ceco - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekurzorová buněčná lymfoblastická leukémie-lymfom - antineoplastická činidla - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

stallergenes, antony array - 2217 alergenovÝ extrakt z dermatophagoides pteronyssinus; 20601 alergenovÝ extrakt z dermatophagoides farinae - sublingvální tableta - 100ir - domÁcÍ prach, roztoČi

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

stallergenes, antony array - 2217 alergenovÝ extrakt z dermatophagoides pteronyssinus; 20601 alergenovÝ extrakt z dermatophagoides farinae; 2217 alergenovÝ extrakt z dermatophagoides pteronyssinus; 20601 alergenovÝ extrakt z dermatophagoides farinae - sublingvální tableta - 100ir+300ir - domÁcÍ prach, roztoČi

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 16461 natrium-mykofenolÁt - enterosolventní tableta - 360mg - kyselina mykofenolovÁ

Unione Europea - ceco - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplasmy prsů - endokrinní terapie - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.